Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess an inhibitory effect of Evogliptin on the progression
of mild-to-moderate aortic stenosis in patients with T2DM and calcific aortic stenosis.